Not Signed In - COX-2 Inhibitors Prescribed To Reduce Gastrointestinal Toxicity Prior To The Market Withdrawals
Sun, 30 Jul 2006 05:00 PM EST
... Nonsteroidal antiinflammatory drugs (NSAIDs) have been the most popular treatment for arthritis - despite their association with gastrointestinal (GI) complications, including bleeding ulcers and death. When selective cyclooxygenase 2 inhibitors (coxibs) were introduced a decade ago, they were widely hailed as a gastroprotective shield for NSAID users. [click link for full article] ...
Related Topics
- COX-2 Inhibitors
- Research
- Gastrointestinal Bleeding
- Gastrointestinal Cancer
- Cerivastatin - Withdrawn From The Market
- Digestive Diseases And Disorders
- ACE Inhibitors
- MAO Inhibitors
- Proton-pump Inhibitors
- Tragacanth
- Development of antibodies (inhibitors) to fibrinogen with treatment
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Rofecoxib Oral Suspension
- Gastrointestinal Carcinoid Tumor
- Endoscopy
- Toxicity/Toxemia
- Digitalis toxicity
- Gastrointestinal
- Stroke, if clots break off and travel to the brain (drugs that thin the blood such as heparin and warfarin can reduce the risk)
- Gastrointestinal blockage
email this page
print this page
bookmark this page
feedback on this page
